# Phase 2 glioblastoma trials recruiting: 77 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 77 trials in phase 2 for glioblastoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 glioblastoma trials: 77 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/glioblastoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 77
- Recruiting or not yet: 77
- Read on: November 19, 2026

## Trials

The 25 newest of 77, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07888647 | IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas | German Cancer Research Center | Phase 2 | Not yet recruiting | Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888647) |
| September 21, 2026 | NCT07831369 | VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma | Inova Health Care Services | Phase 2 | Recruiting | Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4 | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831369) |
| September 15, 2026 | NCT07821112 | Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® | University of California, Irvine | Phase 2 | Not yet recruiting | Glioma, Glioblastoma, GBM, Glioma, Malignant, Astrocytoma, Oligodendroglioma, Elderly Glioblastoma, Elderly GBM | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821112) |
| August 27, 2026 | NCT07789379 | Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Glioblastoma | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789379) |
| August 11, 2026 | NCT07758062 | Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma | Tianjin Medical University General Hospital | Phase 2 | Not yet recruiting | Glioblastoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758062) |
| August 10, 2026 | NCT07754734 | STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation | Dongguan People's Hospital | Phase 2 | Not yet recruiting | Glioma, Glioblastoma (GBM), MGMT-Methylated Glioblastoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754734) |
| July 30, 2026 | NCT07735819 | Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma | Barbara Ann Karmanos Cancer Institute | Phase 2 | Recruiting | Low Grade Glioma, Glioblastoma | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735819) |
| July 20, 2026 | NCT07715097 | Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma | Beijing Tricision Biotherapeutics Inc | Phase 2 | Not yet recruiting | Glioblastoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715097) |
| July 16, 2026 | NCT07708961 | Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma | Mayo Clinic | Phase 2 | Recruiting | Glioblastoma, IDH-Wildtype | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708961) |
| June 25, 2026 | NCT07670026 | Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Glioblastoma | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670026) |
| June 2, 2026 | NCT07620548 | Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas | Washington University School of Medicine | Phase 2 | Not yet recruiting | Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620548) |
| April 13, 2026 | NCT07521657 | Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma | University of Alabama at Birmingham | Phase 2 | Not yet recruiting | Neurofibromatosis 1 (NF1) | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07521657) |
| April 6, 2026 | NCT07511725 | Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Glioblastoma (GBM) | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511725) |
| March 17, 2026 | NCT07476794 | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma | Sunnybrook Health Sciences Centre | Phase 2 | Recruiting | Glioblastoma | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476794) |
| March 10, 2026 | NCT07462507 | Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using \[C-11\]-CS1P1 | Washington University School of Medicine | Phase 2 | Recruiting | Central Nervous System Cancer, Brain Metastases | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462507) |
| February 27, 2026 | NCT07439172 | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. | Cooper Norcross Health | Phase 2 | Recruiting | High Grade Gliomas, Glioblastoma, Astrocytoma, Oligodendroglioma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439172) |
| January 26, 2026 | NCT07365280 | Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma | ZSky Biotech Inc | Phase 2 | Not yet recruiting | Glioblastoma | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365280) |
| January 23, 2026 | NCT07364786 | Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Glioblastoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364786) |
| January 21, 2026 | NCT07356973 | Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma | CRISM Therapeutics LTD | Phase 2 | Recruiting | Glioblastoma | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356973) |
| January 8, 2026 | NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Black Diamond Therapeutics, Inc. | Phase 2 | Recruiting | Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System... | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326566) |
| December 24, 2025 | NCT07301268 | GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade... | Mayo Clinic | Phase 2 | Recruiting | Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301268) |
| December 22, 2025 | NCT07297212 | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent... | BioNTech SE | Phase 2 | Recruiting | Recurrent Glioblastoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297212) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| December 16, 2025 | NCT07284628 | Vortioxetine for Newly Diagnosed Glioblastoma | University of Zurich | Phase 2 | Recruiting | Glioblastoma | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284628) |
| December 4, 2025 | NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial | Centre Hospitalier Universitaire Vaudois | Phase 2 | Recruiting | Glioblastoma, Recurrence Tumor | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263438) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 4 |
| Mayo Clinic | 3 |
| University of Zurich | 2 |
| The University of Texas Health Science Center at San Antonio | 2 |
| Washington University School of Medicine | 2 |
| Tianjin Medical University General Hospital | 2 |
| Tata Memorial Centre | 2 |
| Centre Paul Strauss | 2 |
| Henan Provincial People's Hospital | 2 |
| Brigham and Women's Hospital | 1 |
| ZSky Biotech Inc | 1 |
| Northwell Health | 1 |
| German Cancer Research Center | 1 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 1 |
| University of Alabama at Birmingham | 1 |
| Northwestern University | 1 |
| Peking Union Medical College Hospital | 1 |
| University of Vermont Medical Center | 1 |
| Massachusetts General Hospital | 1 |
| Beijing Tricision Biotherapeutics Inc | 1 |
| Diakonos Oncology Corporation | 1 |
| Sichuan Honghe Biotechnology Co., Ltd. | 1 |
| Baptist Health South Florida | 1 |
| National Neuroscience Institute | 1 |
| M.D. Anderson Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 35 |
| China | 13 |
| Canada | 6 |
| France | 5 |
| Germany | 4 |
| Switzerland | 4 |
| Italy | 4 |
| United Kingdom | 4 |
| Sweden | 3 |
| Australia | 3 |
| Singapore | 2 |
| Netherlands | 2 |
| New Zealand | 2 |
| Greece | 2 |
| Spain | 2 |
| India | 2 |
| Austria | 1 |
| Portugal | 1 |
| Iran | 1 |
| Hungary | 1 |
| Russia | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Playground equipment suppliers in the United States](https://specstream.ai/data/businesses/playground-equipment-suppliers/united-states)
- [Collection agencies in the United States](https://specstream.ai/data/businesses/collection-agencies/united-states)
- [Plumbers in the United States](https://specstream.ai/data/businesses/plumbers/united-states)
- [College counseling companies in the United States](https://specstream.ai/data/businesses/college-counseling-companies/united-states)
- [Podiatrists in the United States](https://specstream.ai/data/businesses/podiatrists/united-states)
- [Colleges and universities in the United States](https://specstream.ai/data/businesses/colleges-and-universities/united-states)
